| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.8 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.0067 | 0.8 |